SynBiotic Future Growth
Future criteria checks 5/6
SynBiotic is forecast to grow earnings and revenue by 107% and 39.7% per annum respectively. EPS is expected to grow by 107.3% per annum. Return on equity is forecast to be 7.7% in 3 years.
Key information
107.0%
Earnings growth rate
107.3%
EPS growth rate
| Pharmaceuticals earnings growth | 21.6% |
| Revenue growth rate | 39.7% |
| Future return on equity | 7.7% |
| Analyst coverage | Low |
| Last updated | 17 Sep 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 34 | 2 | 3 | 3 | 3 |
| 12/31/2025 | 26 | 0 | 1 | 2 | 3 |
| 12/31/2024 | 16 | -2 | -3 | -3 | 3 |
| 12/31/2023 | 4 | -11 | -3 | -3 | N/A |
| 12/31/2022 | 8 | -24 | -7 | -7 | N/A |
| 12/31/2021 | 9 | -13 | -6 | -5 | N/A |
| 12/31/2020 | 5 | -1 | -3 | -1 | N/A |
| 12/31/2019 | N/A | 0 | 0 | 0 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SBX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1%).
Earnings vs Market: SBX is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: SBX is expected to become profitable in the next 3 years.
Revenue vs Market: SBX's revenue (39.7% per year) is forecast to grow faster than the German market (5.6% per year).
High Growth Revenue: SBX's revenue (39.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SBX's Return on Equity is forecast to be low in 3 years time (7.7%).